Growth & Prosperity Blog

Unveiling Platforms, Demonstrating Knowledge: September 15, 2018 Portfolio Update

OIF Portfolio Companies Roll Out Revolutionary Ideas & Address Their Industries

The unmatched expertise and reliable creativity of the Ohio Innovation Fund’s portfolio companies are always drawing eyeballs. Read on to learn about some of our portfolio companies’ new developments and recent engagements.

 

Spirosure Launches New Website for Fenom Pro

breath analysis startupOn Sept. 12, breath analysis device company Spirosure’s brand new product website went live at https://fenomasthma.com. In addition to selling the company’s Fenom Pro™ Asthma Monitor to medical professionals, the site explains in-depth the science of the Fenom Pro device and offers resources for best practices in its use, as well as a rundown on its positive results and reliability.

Take a look at the new site here.

 

Immuta CPO Talks Machine Learning at Data Conference

Cybersecurity Startup FundingAndrew Burt, chief privacy officer and legal engineer for data management company Immuta, spoke at the Strata Data Conference in New York on Sept. 12. Burt’s presentation addressed regulation of machine learning in practice, exploring the risks of machine learning across industries and showing how organizations can accelerate their data science programs if they know how to effectively manage this risk.

Learn more about the presentation here.

Immuta also recently announced a partnership with big data deployment company Cloudera, which you can read about here.

 

National Drug Publication Spotlights Enable Injections’ Delivery Device

Drug Development & Delivery, which publishes the latest scientific methods in drug development, recently released a comprehensive report on the latest innovations in self-injection. A significant portion of the report focuses on self-injection delivery company Enable Injections, exhaustively profiling its enFuse™ On-Body Delivery System, the mechanics behind it and the way it has affected the industry.

Read the report in its entirety here.

“Utilizing the clinic-ready syringe-transfer enFuse OBDS – which supports filling of variable doses – the company will be able to efficiently determine the optimal delivery rate, dose, and user experience prior to committing to the final fixed-dose product configuration for commercial launch.” –Enable Injections Executive VP & Chief Commercial Officer Jeannie Joughin

Enable Injections was also recently featured in a Cincy Inno feature on health-related companies that have raised more than $100,000 – also including OIF portfolio companies – Eccrine Systems Inc. and Genetesis – which you can read here.

 

Interested in more news from each of our portfolio companies on a daily basis? Follow Ohio Innovation Fund on Twitter & Facebook!

 

Unveiling Platforms, Demonstrating Knowledge: September 15, 2018 Portfolio Update